Detection of plasma EV-associated TRAIL by nanoscale flow cytometry for liver metastasis prediction in PDAC.

Chun-Xiang Huang, Jia-Hong Jian, Jun-Sheng Hao, Zi-Wen Zhou, Zhuo-Qun Li, Dong-Ming Kuang, Cai-Yuan Wu
{"title":"Detection of plasma EV-associated TRAIL by nanoscale flow cytometry for liver metastasis prediction in PDAC.","authors":"Chun-Xiang Huang, Jia-Hong Jian, Jun-Sheng Hao, Zi-Wen Zhou, Zhuo-Qun Li, Dong-Ming Kuang, Cai-Yuan Wu","doi":"10.1007/s44307-026-00102-1","DOIUrl":null,"url":null,"abstract":"<p><p>Extracellular vesicles (EVs) mediate tumor-host communication and represent a promising liquid biopsy source for metastasis risk assessment, yet quantitative detection of low-abundance, epitope-defined EV subpopulations in plasma remains technically challenging. Here, we establish a nanoscale flow cytometry workflow on the CytoFLEX platform for sensitive single-EV phenotyping by optimizing violet side scatter (VSSC) triggering, defining an acquisition window that minimizes coincidence or \"swarm\" effects, and applying fluorescence-based analysis with stringent background controls. Using this framework, we quantified EV-associated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) at the single particle level, with good inter-assay reproducibility (CV ~ 11-13%), and resolved low-abundance TRAIL⁺ EVs at approximately 1% abundance within total EV events. Due to the low abundance of EV-associated TRAIL in pancreatic ductal adenocarcinoma (PDAC) plasma, ELISA lacked sufficient analytical sensitivity to accurately reflect EV-associated TRAIL levels, whereas flow-based enumeration preserved quantitative resolution. Clinically, plasma EV-associated TRAIL was significantly elevated in PDAC patients with liver metastasis and demonstrated predictive utility for postoperative liver metastatic recurrence (AUC = 0.766). These results support nanoscale flow cytometry as a robust platform for plasma EV biomarker profiling and identify EV-associated TRAIL as an informative indicator of liver metastatic risk in PDAC.</p>","PeriodicalId":519913,"journal":{"name":"Advanced biotechnology","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12961005/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44307-026-00102-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Extracellular vesicles (EVs) mediate tumor-host communication and represent a promising liquid biopsy source for metastasis risk assessment, yet quantitative detection of low-abundance, epitope-defined EV subpopulations in plasma remains technically challenging. Here, we establish a nanoscale flow cytometry workflow on the CytoFLEX platform for sensitive single-EV phenotyping by optimizing violet side scatter (VSSC) triggering, defining an acquisition window that minimizes coincidence or "swarm" effects, and applying fluorescence-based analysis with stringent background controls. Using this framework, we quantified EV-associated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) at the single particle level, with good inter-assay reproducibility (CV ~ 11-13%), and resolved low-abundance TRAIL⁺ EVs at approximately 1% abundance within total EV events. Due to the low abundance of EV-associated TRAIL in pancreatic ductal adenocarcinoma (PDAC) plasma, ELISA lacked sufficient analytical sensitivity to accurately reflect EV-associated TRAIL levels, whereas flow-based enumeration preserved quantitative resolution. Clinically, plasma EV-associated TRAIL was significantly elevated in PDAC patients with liver metastasis and demonstrated predictive utility for postoperative liver metastatic recurrence (AUC = 0.766). These results support nanoscale flow cytometry as a robust platform for plasma EV biomarker profiling and identify EV-associated TRAIL as an informative indicator of liver metastatic risk in PDAC.

Abstract Image

Abstract Image

Abstract Image

纳米级流式细胞术检测血浆ev相关TRAIL用于预测PDAC患者肝转移。
细胞外囊泡(EVs)介导肿瘤与宿主的交流,是一种很有前途的液体活检来源,用于转移风险评估,然而,在血浆中定量检测低丰度、表位定义的EVs亚群在技术上仍然具有挑战性。在这里,我们在CytoFLEX平台上建立了一个纳米级流式细胞仪工作流程,通过优化紫色侧散射(VSSC)触发,定义一个采集窗口,以最大限度地减少巧合或“群体”效应,并在严格的背景控制下应用基于荧光的分析,来实现敏感的单ev表型。使用该框架,我们在单颗粒水平上量化了EV相关的肿瘤坏死因子相关凋亡诱导配体(TRAIL),具有良好的试验间重复性(CV ~ 11-13%),并在EV总事件中以约1%的丰度分解了TRAIL⁺的EV。由于胰腺导管腺癌(PDAC)血浆中ev相关TRAIL的丰度较低,ELISA缺乏足够的分析灵敏度来准确反映ev相关TRAIL水平,而基于血流的计数法保留了定量分辨率。临床上,伴有肝转移的PDAC患者血浆ev相关TRAIL显著升高,对术后肝转移复发具有预测作用(AUC = 0.766)。这些结果支持纳米级流式细胞术作为血浆EV生物标志物分析的强大平台,并确定EV相关的TRAIL作为PDAC肝转移风险的信息指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书